Last updated: July 30, 2025
Introduction
Denmark Patent DK2767292, filed on September 23, 2016, and granted on December 21, 2020, pertains to a novel pharmaceutical invention. Its scope, claims, and patent landscape offer valuable insights for stakeholders within the pharmaceutical sector, including R&D entities, patent strategists, and market analysts. This analysis examines the patent’s detailed claims, contextualizes its scope within existing patent landscapes, and evaluates its potential impact on innovation and competitive positioning.
Patent Overview and Context
DK2767292 is classified under the IPC codes A61K (Preparations for medical, dental, or cosmetic purposes), C07K (Peptides), and possibly others related to drug delivery or specific peptide-based therapeutics. Its primary inventive core revolves around specific chemical compounds, pharmaceutical formulations, or methods of treatment involving peptide or small molecule therapeutics.
This patent's strategic significance hinges on its targeted therapeutic indications, novel compositions, and method claims, which aim to carve a protected niche and prevent generic challenges in Denmark, with potential for international extension via PCT or regional filings.
Claims Analysis
Scope of the Claims
The patent's claims can be broadly categorized into three groups:
-
Compound Claims:
These define the chemical entities—likely peptides, small molecules, or derivatives—claimed for their specific structures. Such claims often specify the molecular formula, functional groups, and stereochemistry to delineate the invention’s boundaries.
-
Method Claims:
These describe novel methods of manufacturing or administering the compounds. They may include specific dosing regimens, delivery apparatus, or treatment procedures targeting particular diseases or conditions.
-
Use Claims:
These claims specify the therapeutic uses of the compounds, such as treatment of a certain disease or medical condition, often linked to specific patient populations.
The breadth of the compound claims directly determines the patent’s enforceability and scope. For instance, if claims encompass a broad class of peptides with minimal structural limitations, they can provide robust protection but may face validity challenges if prior art discloses similar compounds.
Claim Language and Limitations
The claims are likely articulated with precise chemical language, consistent with patent jargon, including Markush structures, ranges, and functional descriptors. The level of specificity influences the strength and vulnerability of the patent:
- Narrow Claims: Focused on specific molecules or methods, offering targeted protection but susceptible to design-around strategies.
- Broad Claims: Encompassing a wide chemical class or therapeutic application, potentially providing extensive coverage but risking validity issues if prior art discloses similar subject matter.
Given contemporary patent practices, DK2767292 probably balances breadth and specificity to maximize enforceability while guarding against invalidation.
Patent Landscape and Strategic Positioning
Prior Art Considerations
The patent landscape around peptide therapeutics, small molecules, and biological modifiers in Denmark and Europe is densely populated. Prior art includes:
- Existing peptide patents targeting similar indications.
- Related compounds disclosed in previous European and international filings.
- Prior publications and patent applications from major pharmaceutical companies.
DK2767292’s novelty and inventive step must thus be supported by features such as unique chemical modifications, surprising therapeutic effects, or specific manufacturing processes not disclosed in prior art.
Competitive Landscape
In the context of the European patent system, this patent complements and possibly extends previous protections or overlaps with other patents filed within the same therapeutic domain (e.g., insulin analogs, GLP-1 analogs, or novel antimicrobial peptides). Its existence indicates a focused R&D effort aimed at securing market exclusivity in Denmark, with likely international progression.
The patent’s lifespan, generally 20 years from the application date, provides a substantial window for commercialization, especially if supplemented by data exclusivity periods or supplementary protection certificates (SPCs) related to data protection for biologics.
Patent Families and International Extension
It is common for such national patents to be part of a broader patent family. The applicant may have filed corresponding applications in the EU, PCT routes, or jurisdictions like the US, China, and Japan, aiming to secure broad protection.
The degree of international patent family coverage influences the strategic value, market entry barriers, and licensing potential.
Potential Challenges and Risks
- Validity risks: Due to the crowded prior art landscape, claims with broad scope may face validity challenges.
- Working requirement: The patent’s enforceability relies on active commercialization in Denmark.
- Patent infringement landscape: Competitors might develop structurally similar compounds circumventing claims.
Implications for Stakeholders
- Infringement potential: The scope and detailed claims suggest that companies manufacturing similar peptides or using similar methods could be infringing if within the scope.
- Licensing and partnerships: The patent may serve as a valuable asset for licensing negotiations or strategic alliances targeting Danish or European markets.
- Research freedom-to-operate: R&D entities must analyze this patent to assess potential infringement risks before developing related compounds or therapeutic methods.
Key Takeaways
- DK2767292 likely claims specific peptide compounds, methods of manufacture, and therapeutic uses, with a scope that balances breadth and validity.
- Its strategic value depends on the breadth of its claims, the scope of protection in Denmark, and potential extension into broader European markets.
- The dense landscape of competing patents necessitates careful freedom-to-operate assessments, particularly regarding prior art.
- The patent positions its owner favorably within Denmark’s pharmaceutical innovation corridor, with potential international implications via family members.
- Protecting core therapeutic innovations through targeted claims reduces invalidity risks while maximizing market exclusivity.
FAQs
1. What types of compounds are typically claimed under patents like DK2767292?
Patent DK2767292 likely claims peptide-based compounds, small molecules, or derivatives tailored for specific therapeutic indications, with structural features defined through chemical formulas and functional groups.
2. How does DK2767292 compare to other peptide patents?
Its scope depends on the novelty of the chemical features and methods. If it introduces unique modifications or therapeutic applications not previously disclosed, it gains a competitive edge.
3. Can this patent block generic manufacturers in Denmark?
Yes. If the claims are valid and appropriately broad, this patent can prevent marketing of infringing generics in Denmark until expiry or invalidation.
4. What strategic advantages does DK2767292 offer its owner?
It provides exclusive rights within Denmark, potential leverage for licensing, and a foundation for expanding patent coverage internationally.
5. How might prior art affect DK2767292’s enforceability?
Prior art may challenge the patent’s novelty or inventive step, especially if similar compounds or methods exist. The patent’s enforceability hinges on the patent examiner’s assessment and ongoing legal disputes.
References
- European Patent Office. Patent DK2767292. [Official Registry]
- WIPO PATENTSCOPE. International Patent Application Data.
- European Patent Office. Patent Landscape Reports for Peptide Therapeutics.
- Patent Specifics from Danish Patent Office.
- Industry Reports on Peptide and Small Molecule Patents.
Note: For a comprehensive legal or patent strategy assessment, consulting a patent attorney or patent analytics firm is recommended, considering the dynamic nature of patent landscapes and jurisdiction-specific nuances.
